Immune checkpoint blockade in infectious diseases

Nature Reviews Immunology

Volumn 18, Issue 2, 2018, Pages 91-104

  Wykes, Michelle N ^a   Lewin, Sharon R ^b,c  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c ALFRED HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CD134 ANTIGEN; CD69 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GLUCOCORTICOID INDUCED TUMOR NECROSIS FACTOR RECEPTOR; HEPATITIS A VIRUS CELLULAR RECEPTOR 2; HEPATITIS B SURFACE ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PROGRAMMED DEATH 1 RECEPTOR;

ANTIRETROVIRAL THERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHRONIC HEPATITIS B; DENDRITIC CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; IN VIVO STUDY; MALARIA FALCIPARUM; NONHUMAN; OBSERVATIONAL STUDY; PATHOGENESIS; PLASMODIUM BERGHEI INFECTION; PLASMODIUM CHABAUDI INFECTION; PLASMODIUM VIVAX MALARIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY T LYMPHOCYTE; REVIEW; SEROCONVERSION; SIGNAL TRANSDUCTION; TH1 CELL; TUBERCULOSIS; VACCINATION; VIRUS LATENCY; VIRUS REPLICATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOLOGICAL MODEL; COMMUNICABLE DISEASE; HEPATITIS B; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; IMMUNOTHERAPY; LUNG TUBERCULOSIS; MALARIA; NEOPLASM; PROCEDURES; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; T LYMPHOCYTE;

ANIMALS; COMMUNICABLE DISEASES; CTLA-4 ANTIGEN; HEPATITIS B; HIV INFECTIONS; HUMANS; IMMUNE TOLERANCE; IMMUNOTHERAPY; MALARIA; MODELS, IMMUNOLOGICAL; NEOPLASMS; PROGRAMMED CELL DEATH 1 RECEPTOR; SIGNAL TRANSDUCTION; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; T-LYMPHOCYTES; TUBERCULOSIS, PULMONARY;

EID: 85041313801     PISSN: 14741733     EISSN: 14741741     Source Type: Journal    
DOI: 10.1038/nri.2017.112     Document Type: Review

References (171)

1. Baumeister, S. H., Freeman, G. J., Dranoff, G. & Sharpe, A. H. Coinhibitory pathways in immunotherapy for cancer. Annu. Rev. Immunol. 34, 539-573 (2016).
2. Pardoll, D. M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12, 252-264 (2012).
3. Wherry, E. J. T cell exhaustion. Nat. Immunol. 12, 492-499 (2011).
4. Larkin, J. et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373, 23-34 (2015).
5. Brahmer, J. R. et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J. Clin. Oncol. 28, 3167-3175 (2010).
6. Chen, P. L. et al. Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade. Cancer Discov. 6, 827-837 (2016).
7. + CD8 T cells in peripheral blood after PD-1-targeted therapy in lung cancer patients. Proc. Natl Acad. Sci. USA 114, 4993-4998 (2017).
8. Huang, A. C. et al. T-Cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature 545, 60-65 (2017).
9. + T cell immunity. Immunity 45, 333-345 (2016).
10. Cheng, Q., Kyle, D. E. & Gatton, M. L. Artemisinin resistance in Plasmodium falciparum: a process linked to dormancy? Int. J. Parasitol. Drugs Drug Resist. 2, 249-255 (2012).
11. World Health Organization. World Malaria Report (WHO, 2016).
12. Olotu, A. et al. Four-year efficacy of RTS, S/AS01E and its interaction with malaria exposure. N. Engl. J. Med. 368, 1111-1120 (2013).
13. Barragan, A., Kremsner, P. G., Weiss, W., Wahlgren, M. & Carlson, J. Age-related buildup of humoral immunity against epitopes for rosette formation and agglutination in African areas of malaria endemicity. Infect. Immun. 66, 4783-4787 (1998).
14. Bull, P. C. et al. Parasite antigens on the infected red cell surface are targets for naturally acquired immunity to malaria. Nat. Med. 4, 358-360 (1998).
15. Soe, S. et al. Premunition against Plasmodium falciparum in a malaria hyperendemic village in Myanmar. Trans. R. Soc. Trop. Med. Hyg. 95, 81-84 (2001).
16. Mazier, D. et al. Hepatic phase of malaria is the target of cellular mechanisms induced by the previous and the subsequent stages. A crucial role for liver nonparenchymal cells. Immunol. Lett. 25, 65-70 (1990).
17. Cohen, S., McGregor, I. & Carrington, S. Gamma-globulin and acquired immunity to human malaria. Nature 192, 733-737 (1961).
18. + T cells in the protective immune response to Plasmodium chabaudi in vivo. Immunol. Lett. 25, 101-107 (1990).
19. + T lymphocytes both contribute to acquired immunity to blood-stage Plasmodium chabaudi AS. Infect. Immun. 59, 51-58 (1991).
20. von der Weid, T., Honarvar, N. & Langhorne, J. Gene-targeted mice lacking B cells are unable to eliminate a blood stage malaria infection. J. Immunol. 156, 2510-2516 (1996).
21. + T cells drives chronic malaria. Cell Rep. 5, 1204-1213 (2013).
22. + T cells in long-term immunity against blood-stage malaria. Sci. Rep. 6, 26210 (2016).
23. Wykes, M. N., Zhou, Y. H., Liu, X. Q. & Good, M. F. Plasmodium yoelii can ablate vaccine-induced long-term protection in mice. J. Immunol. 175, 2510-2516 (2005).
24. Liu, X. Q. et al. Malaria infection alters the expression of B-cell activating factor resulting in diminished memory antibody responses and survival. Eur. J. Immunol. 42, 3291-3301 (2012).
25. Pierce, S. K. & Miller, L. H. World Malaria Day 2009: what malaria knows about the immune system that immunologists still do not. J. Immunol. 182, 5171-5177 (2009).
26. Butler, N. S. et al. Therapeutic blockade of PD-L1 and LAG-3 rapidly clears established blood-stage Plasmodium infection. Nat. Immunol. 13, 188-195 (2012).
27. Illingworth, J. et al. Chronic exposure to Plasmodium falciparum is associated with phenotypic evidence of B and T cell exhaustion. J. Immunol. 190, 1038-1047 (2013).
28. + regulatory T cell subsets circulating in human malaria. Microbes Infect. 18, 639-648 (2016).
29. Hou, N. et al. T-Cell immunoglobulin- and mucin-domain-containing molecule 3 signaling blockade improves cell-mediated immunity against malaria. J. Infect. Dis. 214, 1547-1556 (2016).
30. Zander, R. A. et al. PD-1 co-inhibitory and OX40 co-stimulatory crosstalk regulates helper T cell differentiation and anti-plasmodium humoral immunity. Cell Host Microbe 17, 628-641 (2015).
31. Hafalla, J. C. et al. The CTLA-4 and PD-1/PD-L1 inhibitory pathways independently regulate host resistance to plasmodium-induced acute immune pathology. PLoS Pathog. 8, e1002504 (2012).
32. Hisaeda, H. et al. Resistance of regulatory T cells to glucocorticoid-induced TNFR family-related protein (GITR) during Plasmodium yoelii infection. Eur. J. Immunol. 35, 3516-3524 (2005).
33. Lepenies, B. et al. Ligation of B and T lymphocyte attenuator prevents the genesis of experimental cerebral malaria. J. Immunol. 179, 4093-4100 (2007).
34. GBD 2015 HIV Collaborators et al. Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980-2015: the Global Burden of Disease Study 2015. Lancet HIV 3, e361-e387 (2016).
35. Deeks, S. G. et al. International AIDS Society global scientific strategy: towards an HIV cure 2016. Nat. Med. 22, 839-850 (2016).
36. + T cells leads to reversible immune dysfunction. Nat. Med. 12, 1198-1202 (2006).
37. + T cells correlates with disease progression and defines a reversible immune dysfunction. Nat. Immunol. 8, 1246-1254 (2007).
38. Chew, G. M. et al. TIGIT marks exhausted T cells, correlates with disease progression, and serves as a target for immune restoration in HIV and SIV Infection. PLoS Pathog. 12, e1005349 (2016).
39. + T cell exhaustion marker expression. AIDS Res Hum Retroviruses 33, 658-667 (2017).
40. + T-cell exhaustion in typical progressors but not in long-term nonprogressors. Blood 109, 4671-4678 (2007).
41. Tian, X. et al. The upregulation of LAG-3 on T cells defines a subpopulation with functional exhaustion and correlates with disease progression in HIV-infected subjects. J. Immunol. 194, 3873-3882 (2015).
42. Sauce, D. et al. PD-1 expression on human CD8 T cells depends on both state of differentiation and activation status. AIDS 21, 2005-2013 (2007).
43. Day, C. L. et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 443, 350-354 (2006).
44. + T cell survival in HIV infection. J. Exp. Med. 203, 2281-2292 (2006).
45. +follicular cytotoxic T cells control viral infection in B cell follicles. Nat. Immunol. 17, 1187-1196 (2016).
46. +CD8 T cells during chronic SIV infection. Proc. Natl Acad. Sci. USA 114, 1976-1981 (2017).
47. + cells in vivo. J. Virol. 90, 11168-11180 (2016).
48. Hoffmann, M. et al. Exhaustion of activated CD8 T cells predicts disease progression in primary HIV-1 Infection. PLoS Pathog. 12, e1005661 (2016).
49. Shive, C. L. et al. Inflammation perturbs the IL-7 axis, promoting senescence and exhaustion that broadly characterize immune failure in treated HIV infection. J. Acquir. Immune Def. Syndr. 71, 483-492 (2016).
50. Sinha, A. et al. role of T-cell dysfunction, inflammation, and coagulation in microvascular disease in HIV. J. Am. Heart Assoc. 5, e004243 (2016).
51. Kelesidis, T. et al. Oxidized lipoproteins are associated with markers of inflammation and immune activation in HIV-1 infection. AIDS 30, 2625-2633 (2016).
52. Hurst, J. et al. Immunological biomarkers predict HIV-1 viral rebound after treatment interruption. Nat. Commun. 6, 8495 (2015).
53. + T cell killing. PLoS Pathog. 11, e1005224 (2015).
54. Velu, V. et al. Enhancing SIV-specific immunity in vivo by PD-1 blockade. Nature 458, 206-210 (2009).
55. Dyavar Shetty, R. et al. PD-1 blockade during chronic SIV infection reduces hyperimmune activation and microbial translocation in rhesus macaques. J. Clin. Invest. 122, 1712-1716 (2012).
56. Mylvaganam, G. H. et al. PD-1 blockade synergizes with ART for restoring anti-viral CD8 T cell function and possibly destabilizing the viral reservoir in SIV infected macaques [Abstract 9016]. Presented at the International AIDS Conference, Durban, South Africa, July 2016.
57. Gill, A. L. et al. Programed death-1/programed death-ligand 1 expression in lymph nodes of HIV infected patients: results of a pilot safety study in rhesus macaques using anti-programed death-ligand 1 (Avelumab). AIDS 30, 2487-2493 (2016).
58. Cecchinato, V. et al. Immune activation driven by CTLA-4 blockade augments viral replication at mucosal sites in simian immunodeficiency virus infection. J. Immunol. 180, 5439-5447 (2008).
59. Hryniewicz, A. et al. CTLA-4 blockade decreases TGF- β, IDO, and viral RNA expression in tissues of SIVmac251-infected macaques. Blood 108, 3834-3842 (2006).
60. + T cell TIGIT/CD226/PVR axis despite early initiation of antiretroviral treatment in HIV infected individuals. Sci. Rep. 7, 40354 (2017).
61. Anderson, A. C., Joller, N. & Kuchroo, V. K. Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation. Immunity 44, 989-1004 (2016).
62. Chatterjee, S. et al. A humanized antibody for imaging immune checkpoint ligand PD-L1 expression in tumors. Oncotarget 7, 10215-10227 (2016).
63. Chomont, N. et al. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat. Med. 15, 893-900 (2009).
64. + T cells expressing PD-1, TIGIT and LAG-3 contribute to HIV persistence during ART. PLoS Pathog. 12, e1005761 (2016).
65. + T cells.. J. Infect. Dis. 208, 50-56 (2013).
66. + T cells in treated and untreated HIV disease. AIDS 28, 1749-1758 (2014).
67. + and follicular helper T cells are responsible for persistent HIV-1 transcription in treated aviremic individuals. Nat. Med. 22, 754-761 (2016).
68. Khoury, G. et al. HIV persistence and T-cell activation in blood, rectal and lymph node tissue in HIV-infected individuals receiving suppressive ART. J. Infect. Dis. 215, 911-919 (2017).
69. El-Far, M. et al. Nef promotes evasion of human immunodeficiency virus type 1-infected cells from the CTLA-4-mediated inhibition of T-cell activation. J. Gen. Virol. 96, 1463-1477 (2015).
70. El-Far, M. et al. Down-regulation of CTLA-4 by HIV-1 Nef protein. PLoS ONE 8, e54295 (2013).
71. Wightman, F. et al. Effect of ipilimumab on the HIV reservoir in an HIV-infected individual with metastatic melanoma. AIDS 29, 504-506 (2015).
72. Van der Sluis, R. M. et al. Anti-PD-1 disrupts HIV latency in non-proliferating but not in proliferating T-cells [Abstract OA3-3]. J. Virus Eradication 3, Suppl. 1 (2017).
73. Gay, C. L. et al. Clinical trial of the anti-PD-L1 antibody BMS-936559 in HIV-1 infected participants on suppressive antiretroviral therapy. J. Infect. Dis. 215, 1725-1733 (2017).
74. Rasmussen, T. A., Anderson, J. L., Wightman, F. & Lewin, S. R. Cancer therapies in HIV cure research. Curr. Opin. HIV AIDS 12, 96-104 (2017).
75. Romano, E. et al. Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients. Proc. Natl Acad. Sci. USA 112, 6140-6145 (2015).
76. Dahan, R. et al. FcγRs modulate the anti-tumor activity of antibodies targeting the PD-1/PD-L1 axis. Cancer Cell 28, 285-295 (2015).
77. + T cells in mice. J. Clin. Invest. 123, 2629-2642 (2013).
78. Schweitzer, A., Horn, J., Mikolajczyk, R. T., Krause, G. & Ott, J. J. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet 386, 1546-1555 (2015).
79. Stanaway, J. D. et al. The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. Lancet 388, 1081-1088 (2016).
80. Revill, P., Testoni, B., Locarnini, S. & Zoulim, F. Global strategies are required to cure and eliminate HBV infection. Nat. Rev. Gastroenterol. Hepatol. 13, 239-248 (2016).
81. Guidotti, L. G., Isogawa, M. & Chisari, F. V. Host-virus interactions in hepatitis B virus infection. Curr. Opin. Immunol. 36, 61-66 (2015).
82. Chang, J. J. et al. The phenotype of hepatitis B virus-specific T cells differ in the liver and blood in chronic hepatitis B virus infection. Hepatology 46, 1332-1340 (2007).
83. Boni, C. et al. Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. J. Virol. 81, 4215-4225 (2007).
84. Nebbia, G. et al. Upregulation of the Tim-3/galectin-9 pathway of T cell exhaustion in chronic hepatitis B virus infection. PLoS ONE 7, e47648 (2012).
85. + T cell function by PD-1 blockade in inactive carrier patients is linked to T cell differentiation. J. Hepatol. 61, 1212-1219 (2014).
86. Schurich, A. et al. Role of the coinhibitory receptor cytotoxic T lymphocyte antigen-4 on apoptosis-prone CD8 T cells in persistent hepatitis B virus infection. Hepatology 53, 1494-1503 (2011).
87. Zhang, Z. et al. Dynamic programmed death 1 expression by virus-specific CD8 T cells correlates with the outcome of acute hepatitis B. Gastroenterology 134, 1938-1949 (2008).
88. + B Cells with the progression of Hepatitis B virus infection. Viral Immunol. 30, 224-231 (2017).
89. + T-cells is characterized by high PD-1 expression but absent coregulation of multiple inhibitory molecules. PLoS ONE 9, e105703 (2014).
90. Fisicaro, P. et al. Targeting mitochondrial dysfunction can restore antiviral activity of exhausted HBV-specific CD8 T cells in chronic hepatitis B. Nat. Med. 23, 327-336 (2017).
91. + cells in liver damage and viral control during persistent hepatitis B virus infection. J. Exp. Med. 191, 1269-1280 (2000).
92. + T cells with regulatory properties in chronic hepatitis B virus infection. Cell. Immunol. 311, 36-45 (2017).
93. Fisicaro, P. et al. Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B. Gastroenterology 138, 682-693 (2010).
94. + T-cell function. Hepatology 52, 1934-1947 (2010).
95. + T cell effector functions after antigen recognition in the liver. Immunity 23, 53-63 (2005).
96. + T lymphocytes in the liver. J. Immunol. 178, 2714-2720 (2007).
97. Zhang, E. et al. The expression of PD-1 ligands and their involvement in regulation of T cell functions in acute and chronic woodchuck hepatitis virus infection. PLoS ONE 6, e26196 (2011).
98. Liu, J. et al. Enhancing virus-specific immunity in vivo by combining therapeutic vaccination and PD-L1 blockade in chronic hepadnaviral infection. PLoS Pathog. 10, e1003856 (2014).
99. Gane, E. J. et al. A phase 1 study evaluating anti-PD-1 treatment with or without GS-4774 in HBeAg negative chronic hepatitis B patients [Abstract]. Eur. Associ. Study Liver Dis. (2017).
100. El-Khoueiry, A. B. et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet http://dx.doi.org/10.1016/S0140-6736(17)31046-2 (2017).
101. + T-cell subsets; potential correlates of containment in HIV-TB co-Infection. PLoS ONE 11, e0146905 (2016).
102. Boer, M. C. et al. KLRG1 and PD-1 expression are increased on T-cells following tuberculosis-treatment and identify cells with different proliferative capacities in BCG-vaccinated adults. Tuberculosis (Edinb). 97, 163-171 (2016).
103. Barber, D. L., Mayer-Barber, K. D., Feng, C. G., Sharpe, A. H. & Sher, A. CD4 T cells promote rather than control tuberculosis in the absence of PD-1-mediated inhibition. J. Immunol. 186, 1598-1607 (2011).
104. Tousif, S. et al. T cells from programmed death-1 deficient mice respond poorly to Mycobacterium tuberculosis infection. PLoS ONE 6, e19864 (2011).
105. Lazar-Molnar, E. et al. Programmed death-1 (PD-1)- deficient mice are extraordinarily sensitive to tuberculosis. Proc. Natl Acad. Sci. USA 107, 13402-13407 (2010).
106. Jayaraman, P. et al. TIM3 mediates T cell exhaustion during Mycobacterium tuberculosis infection. PLoS Pathog. 12, e1005490 (2016).
107. Sotgiu, G., Centis, R., D'Ambrosio, L. & Migliori, G. B. Tuberculosis treatment and drug regimens. Cold Spring Harb. Perspect Med. 5, a017822 (2015).
108. Attanasio, J. & Wherry, E. J. Costimulatory and coinhibitory receptor pathways in infectious disease. Immunity 44, 1052-1068 (2016).
109. Harding, F. A., McArthur, J. G., Gross, J. A., Raulet, D. H. & Allison, J. P. CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature 356, 607-609 (1992).
110. Krummel, M. F. & Allison, J. P. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J. Exp. Med. 182, 459-465 (1995).
111. Freeman, G. J. et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med. 192, 1027-1034 (2000).
112. Keir, M. E., Butte, M. J., Freeman, G. J. & Sharpe, A. H. PD-1 and its ligands in tolerance and immunity. Annu. Rev. Immunol. 26, 677-704 (2008).
113. Chemnitz, J. M., Parry, R. V., Nichols, K. E., June, C. H. & Riley, J. L. SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J. Immunol. 173, 945-954 (2004).
114. Francisco, L. M. et al. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J. Exp. Med. 206, 3015-3029 (2009).
115. Kamphorst, A. O. et al. Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent. Science 355, 1423-1427 (2017).
116. Yamazaki, T. et al. Expression of programmed death 1 ligands by murine T cells and APC. J. Immunol. 169, 5538-5545 (2002).
117. Keir, M. E. et al. Tissue expression of PD-L1 mediates peripheral T cell tolerance. J. Exp. Med. 203, 883-895 (2006).
118. Brown, J. A. et al. Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. J. Immunol. 170, 1257-1266 (2003).
119. Liang, S. C. et al. Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses. Eur. J. Immunol. 33, 2706-2716 (2003).
120. Balar, A. V. et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet 389, 67-76 (2017).
121. Rittmeyer, A. et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 389, 255-265 (2017).
122. Homet Moreno, B., Mok, S., Comin-Anduix, B., Hu-Lieskovan, S. & Ribas, A. Combined treatment with dabrafenib and trametinib with immune-stimulating antibodies for BRAF mutant melanoma. Oncoimmunol. 5, e1052212 (2016).
123. Latchman, Y. et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat. Immunol. 2, 261-268 (2001).
124. Zhang, Y. et al. Regulation of T cell activation and tolerance by PDL2. Proc. Natl Acad. Sci. USA 103, 11695-11700 (2006).
125. Tseng, S. Y. et al. B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells. J. Exp. Med. 193, 839-846 (2001).
126. + T cells independent of the PD-1 receptor. J. Exp. Med. 198, 31-38 (2003).
127. Shin, T. et al. In vivo costimulatory role of B7-DC in tuning T. helper cell 1 and cytotoxic T. lymphocyte responses. J. Exp. Med. 201, 1531-1541 (2005).
128. Michot, J. M. et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur. J. Cancer 54, 139-148 (2016).
129. Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711-723 (2010).
130. Topalian, S. L. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443-2454 (2012).
131. Brahmer, J. R. et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366, 2455-2465 (2012).
132. Weber, J. S., Postow, M., Lao, C. D. & Schadendorf, D. Management of adverse events following treatment with anti-programmed death-1 agents. Oncologist 21, 1230-1240 (2016).
133. Topalian, S. L. et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J. Clin. Oncol. 32, 1020-1030 (2014).
134. Barber, D. L. et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439, 682-687 (2006).
135. + T cell exhaustion during chronic viral infection. Immunity 27, 670-684 (2007).
136. Youngblood, B. et al. Cutting edge: prolonged exposure to HIV reinforces a poised epigenetic program for PD-1 expression in virus-specific CD8 T cells. J. Immunol. 191, 540-544 (2013).
137. Ahn, E. et al. Demethylation of the PD-1 promoter is imprinted during the effector phase of CD8 T cell exhaustion. J. Virol. 90, 8934-8946 (2016).
138. Pauken, K. E. et al. Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade. Science 354, 1160-1165 (2016).
139. Sen, D. R. et al. The epigenetic landscape of T cell exhaustion. Science 354, 1165-1169 (2016).
140. Zhu, C. et al. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat. Immunol. 6, 1245-1252 (2005).
141. + T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia. Blood 117, 4501-4510 (2011).
142. Sakuishi, K. et al. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J. Exp. Med. 207, 2187-2194 (2010).
143. Huang, C. T. et al. Role of LAG-3 in regulatory T cells. Immunity 21, 503-513 (2004).
144. Woo, S. R. et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res. 72, 917-927 (2012).
145. Dougall, W. C., Kurtulus, S., Smyth, M. J. & Anderson, A. C. TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy. Immunol. Rev. 276, 112-120 (2017).
146. Lozano, E., Dominguez-Villar, M., Kuchroo, V. & Hafler, D. A. The TIGIT/CD226 axis regulates human T cell function. J. Immunol. 188, 3869-3875 (2012).
147. Yu, X. et al. The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. Nat. Immunol. 10, 48-57 (2009).
148. Blake, S. J., Dougall, W. C., Miles, J. J., Teng, M. W. & Smyth, M. J. Molecular pathways: targeting CD96 and TIGIT for cancer immunotherapy. Clin. Cancer Res. 22, 5183-5188 (2016).
149. Gonzalez, L. C. et al. A coreceptor interaction between the CD28 and TNF receptor family members B and T lymphocyte attenuator and herpesvirus entry mediator. Proc. Natl Acad. Sci. USA 102, 1116-1121 (2005).
150. Sedy, J. R. et al. B and T lymphocyte attenuator regulates T cell activation through interaction with herpesvirus entry mediator. Nat. Immunol. 6, 90-98 (2005).
151. Cai, G. & Freeman, G. J. The CD160, BTLA, LIGHT/HVEM pathway: a bidirectional switch regulating T-cell activation. Immunol. Rev. 229, 244-258 (2009).
152. + T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1. Cancer Res. 72, 887-896 (2012).
153. Ephrem, A. et al. Modulation of Treg cells/T effector function by GITR signaling is context-dependent. Eur. J. Immunol. 43, 2421-2429 (2013).
154. + regulatory T cells through GITR breaks immunological self-tolerance. Nat. Immunol. 3, 135-142 (2002).
155. Schaer, D. A., Cohen, A. D. & Wolchok, J. D. Anti-GITR antibodies - potential clinical applications for tumor immunotherapy. Curr. Opin. Investig. Drugs 11, 1378-1386 (2010).
156. Mitsui, J. et al. Two distinct mechanisms of augmented antitumor activity by modulation of immunostimulatory/inhibitory signals. Clin. Cancer Res. 16, 2781-2791 (2010).
157. Deng, J., Le Mercier, I., Kuta, A. & Noelle, R. J. A new VISTA on combination therapy for negative checkpoint regulator blockade. J. Immunother. Cancer 4, 86 (2016).
158. Gao, J. et al. VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer. Nat. Med, 23, 551-555 (2017).
159. Freeman, G. J., Wherry, E. J., Ahmed, R. & Sharpe, A. H. Reinvigorating exhausted HIV-specific T cells via PD-1-PD-1 ligand blockade. J. Exp. Med. 203, 2223-2227 (2006).
160. Kaufmann, D. E. & Walker, B. D. PD-1 and CTLA-4 inhibitory cosignaling pathways in HIV infection and the potential for therapeutic intervention. J. Immunol. 182, 5891-5897 (2009).
161. + T cells associated with reversible immune dysfunction. J. Virol. 81, 9249-9258 (2007).
162. Nakamoto, N. et al. Functional restoration of HCV-specific CD8 T cells by PD-1 blockade is defined by PD-1 expression and compartmentalization. Gastroenterology 134, 1927-1937 (2008).
163. + T cell responses in a hepatitis C virus core murine model. J. Immunol. 180, 4875-4884 (2008).
164. Urbani, S. et al. Restoration of HCV-specific T cell functions by PD-1/PD-L1 blockade in HCV infection: effect of viremia levels and antiviral treatment. J. Hepatol. 48, 548-558 (2008).
165. + T cells. J. Virol. 88, 1636-1651 (2014).
166. Sharma, S. et al. T cell immunoglobulin and mucin protein-3 (Tim-3)/Galectin-9 interaction regulates influenza A virus-specific humoral and CD8 T-cell responses. Proc. Natl Acad. Sci. USA 108, 19001-19006 (2011).
167. Xu, D. et al. A potential new pathway for PD-L1 costimulation of the CD8-T cell response to Listeria monocytogenes infection. PLoS ONE 8, e56539 (2013).
168. + T-cell response via PD-1-PDL-1 blockade. Proc. Natl Acad. Sci. USA 108, 9196-9201 (2011).
169. + T cell exhaustion. J. Immunol. 190, 3380-3389 (2013).
170. Esch, K. J., Juelsgaard, R., Martinez, P. A., Jones, D. E. & Petersen, C. A. Programmed death 1-mediated T cell exhaustion during visceral leishmaniasis impairs phagocyte function. J. Immunol. 191, 5542-5550 (2013).
171. + T cells and confers protection against Leishmania donovani infections. PLoS Pathog. 5, e1000431 (2009).